When a scientist discovers a new drug to cure a disease, it’s cheers all around. But what happens next? How is the drug produced for commercialization so that it can actually be administered to a patient?
That’s where Michael Betenbaugh, a Whiting School of Engineering professor of chemical and biomolecular engineering, comes in. He and his laboratory team are working with researchers at MedImmune to develop a more efficient media in which to grow the microbes used to produce genetically engineered human antibodies for testing, development and commercialization.